The nation of Zimbabwe has rejected a significant US healthcare agreement valued at 367 million US dollars (£272m) over five years because of the United States' insistence on confidential biological samples.
This rejection came to light after a official document from December was disclosed, indicating that President Emmerson Mnangagwa felt the arrangement was "lopsided".
An official representative has since explained that the US was demanding access to genetic material for scientific study and commercial gain but refused to guarantee the benefits from any future vaccines.
"We are forced to start the challenging and unfortunate task of winding down our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had donated over $1.9bn as health assistance to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has appealed for further talks to reach a deal agreeable to both sides so the nation's vital HIV treatment initiative can continue.
Broader Context
This development follows a similar situation in Kenya, where a court halted a similar deal with the US after concerns were filed about the security of Kenyans' medical information.
After returning to office last year, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
USAID had administered assistance for the US government, but Trump stated its spending was "wasteful" and his administration was pursuing government-to-government agreements to boost transparency and responsibility.
According to reports, Sixteen nations in Africa have to date agreed to similar agreements, representing more than $18.3bn in new funding.
Details of the Declined Agreement
The money for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this partnership would have delivered immense advantages for Zimbabwean communities, especially the 1.2 million presently on HIV treatment through American-funded initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana said the proposed deal was "unfair".
"Our nation was requested to provide its biological resources and data indefinitely, without any equivalent guarantee of benefiting from any scientific breakthroughs – like new medicines or tests – that could result from that shared data," his statement read.
"Put simply, our nation would provide the basic resources for medical research without any certainty that the end products would be accessible to our citizens should a future health crisis arise."
National Interest and International Frameworks
He also noted that the American exit from the global health body and its push of one-on-one deals were undermining structures already established through the global organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing system designed to manage potential pandemics.
"This framework is designed to ensure that when a country contributes its samples, the resulting advantages – including vaccines and treatments – are shared equitably, not commercialised exclusively by those with the capability to develop them."
These objections regarding the US deal "should not be misconstrued as opposition to America," he added.
"We are open to ongoing discussions with our American counterparts on how subsequent collaboration might be arranged in a way that honours the independence and interests of each country."
Medical Community Response
A leading public health body said it recognised the official position, but suggested that negotiations need to persist since much of the country's Aids initiatives were funded by external financing.
"If specific concerns arise, such as those relating to information security or implementation frameworks, these can frequently be addressed via technical clarification and negotiated safeguards," it added.
This impasse emphasises the complex debate between receiving much-needed international aid and safeguarding a country's data in an ever more data-driven world.